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Abstract
Despite the important improvements made in the fields of surgery, chemotherapy and radiation therapy, pancreatic
cancer remains one of the most lethal malignancies. Improved outcomes with novel chemotherapy regimes led
again to increased attention on the role of localized radiotherapy, since local tumor progression causes significant
morbidity and mortality in patients. Even after resection local failure rates are as high as 50–80%. The immediate
proximity to critical structures (bone marrow, spinal cord, kidneys, liver, and intestine) limits the dose of radiation
that can be administered to the tumor bed with conventional external beam radiation therapy (EBRT). The
intraoperative radiotherapy (IORT) appears to be an ideal therapeutic strategy for this disease, having the advantage
of enabling the delivery of high doses of radiation to areas that are at risk for microscopic disease, saving critical
organs and reducing the possibility of inducing radiotoxicity. This technique allows a theoretical increase in the
radiation therapeutic index to tumor compared to the adjacent organs at risk (OAR). The aim of this review is to
update and comment on IORT in the multidisciplinary management of pancreatic cancer.
Background
Pancreatic cancer is the fourth commonest cause of
death from cancer in men and women [1, 2]. Surgical
therapy currently offers the only potential monomodal
cure for pancreatic adenocarcinoma [3]. However, only a
few patients present with tumors that are amenable to
resection, and even after resection of localized cancers,
long-term survival is rare. At presentation, only 10–20%
of patients with pancreatic adenocarcinoma have poten-
tially resectable cancers, 40% have locally advanced
unresectable tumors, and 40% have metastatic disease.
Adenocarcinoma of the pancreas has a 5-year survival
rate of only 4% [2]. In spite of the progress in surgical
treatment, resulting in increased resection rates and a
decrease in treatment-related morbidity and mortality,
resection has failed to improve long-term survival [3].
By histological evaluation < 15% of the patients undergo-
ing R0 resection have a pN0 status, >50% suffer from
lymphangiosis carcinomatosa, and > 50% suffer from
extrapancreatic nerve plexus infiltration [4, 5]. Combined
modality treatment approaches using chemotherapy or
chemoradiation in addition to surgery are the mainstay in
treatment of pancreatic cancer [4–8].
Achievements of surgery
Although surgery offers a low cure rate, it is also the
only chance for cure. Regarding long-term survival after
R0 resection, only 3–16% of the patients from selected
series survived 5 years or more. Locoregional recurrence
and/or metastatic disease develop in the majority of pa-
tients who undergo pancreatic resection. Relapse occurs
within 9–15 months after initial presentation and patients
have median life expectancies of only 12–15 months with-
out adjuvant therapy. The 5-year survival rate of patients
with resected pancreatic adenocarcinoma is approximately
10% [3]. The statistics for the 80–90% of patients who
present with locally advanced and metastatic pancreatic
cancer are even more dismal. Rarely do such patients
achieve a complete response to treatment; median survival
is 5–10 months and 5-year survival is near zero [6].
The cardinal rule in improving the prognosis in pa-
tients with pancreatic cancer proved to be complete
tumor removal in patients undergoing oncological resec-
tion [3, 4]. In most recent published prospective trials,
R0 resection results in an increase of survival in com-
parison with patients with a residual tumor [7, 8]. How-
ever, R0 resection fails to improve long-term survival
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[4]. More than 95% of the patients undergoing surgical
resection are at an advanced stage of cancer. Potentially
curative resection is hampered by a failure to include re-
mote cancer cell-positive tissues in the operative speci-
men, i.e. N2 lymph nodes, nerve plexus, and perivascular
tissue [9, 10]. Cancer recurrence after resection with cura-
tive intent is the consequence of cancer cell-positive tis-
sues left behind. However, comparison of the survival
times after standard and extended resection of pancreatic
cancers indicated that no significant long-term survival
benefit resulted from extended R0 resection [11, 12].
Dissemination pattern of pancreatic cancer
Using molecular biological methods like reverse tran-
scriptase polymerase chain reaction (RT-PCR) or immu-
nostaining, a new dimension of micrometastasis has
been objectified. With the higher sensitivity of these mo-
lecular biological methods, up to 60% of lymph nodes
previously seen as microscopically free of cancer showed
micrometastasis by RT-PCR even in UICC stage I or II
cancers [5, 13]. Nerve plexus invasion outside of the
pancreas has been observed in 43–72% of patients
[14, 15]. Further, careful histopathological evaluation of
cancer dissemination has demonstrated that even in stage
I and II cancers, lymph vessels surrounding the pancreas
are cancer cell infiltrated in most of the cases [5, 15].
This knowledge about cancer cell dissemination early
in the course of pancreatic cancer, including early stage
cancers, explains why true R0 resection in pancreatic
cancer is difficult to achieve, and explains the observed
frequency of recurrence in >95% of patients undergoing
surgical resection with curative intent.
Combined modality treatment
Both distant and local/regional patterns of recurrence
are common, and this suggests that most patients have
occult metastatic or local/regional disease (or both) at
the time of resection. According to several phase II or
III trials, combined modality treatment approaches using
chemotherapy or chemoradiation in addition to surgery
can achieve improvement in locoregional control and
survival [7, 8, 16]. Novel systemic treatment regimens
like FOLFIRINOX and nab-paclitaxel have demonstrated
improvements in prolonging survival in advanced cases,
but long-term survival is still scarce [17, 18].
Radiation therapy dose escalation
Several trials could show that dose escalation in radi-
ation therapy resulted in improved local control in com-
bination with potentially curative resection [19–21]. The
efficacy of external beam radiation therapy (EBRT) in
pancreatic cancer is limited by the inability to deliver ad-
equate doses of irradiation secondary to the dose toler-
ance limits of small bowel, spinal cord, stomach, kidney,
and liver. Further, the use of combined modality ap-
proaches in pancreatic cancer is associated with in-
creased gastrointestinal toxicity. Technical developments
like Intraoperative Radiation Therapy (IORT) have the
potential to significantly improve radiation therapy of
pancreatic cancers by reducing normal tissue dose, and
simultaneously allow for escalation of dose to further en-
hance locoregional control [21, 22].
Intraoperative Radiation
Intraoperative radiation therapy (IORT) techniques
allow for the delivery of high doses of radiation therapy
while excluding part or all of the nearby dose-limiting
sensitive structures. Therefore, the effective radiation
dose is increased and local tumor control potentially im-
proved. This is pertinent in the case of pancreatic cancer
because local failure rates are as high as 50–80% in pa-
tients with resected and locally advanced disease [10]. In
pancreatic cancer, IORT has been offered for unresect-
able tumors to provide local tumor control and palli-
ation of pain, and for resectable tumors in an effort to
improve local control and survival after PD [21].
Technique of IORT
Intraoperative radiation therapy is defined as the appli-
cation of a single fraction of high dose irradiation during
a surgical procedure. The target volume is usually the
tumor bed after gross total resection or the remaining
gross residual disease if resection was not (completely)
possible. IORT is typically used as a boost after pre-
operative or prior to postoperative EBRT. The use of
IORT alone should be restricted to situations without a
reasonable opportunity for EBRT (for example recur-
rence after prior irradiation). Technically, two major ap-
proaches are in use for IORT treatments of pancreatic
cancer: electrons and HDR-brachytherapy [23, 24]. After
surgical removal of the tumor, the target volume is de-
fined by the radiation oncologist in correspondence with
the treating surgeon (Figs. 1 and 2). An IORT boost of-
fers several advantages compared to an EBRT boost: first
of all, radiosensitive structures or organs at risk can be
surgically moved out of the radiation field and therefore
effectively spared from radiation exposure. Target volume
definition takes place under visual control which mini-
mizes a possible geographical miss. Safety margins can be
kept to a minimum as no substantial intra- or interfrac-
tional movements have to be taken into account and
finally overall treatment time is shortened. These advan-
tages have to be weighed against some drawbacks: No
final pathological assessment of margin status will usually
be available for treatment stratification. Late toxicity
might be increased at least theoretically due to the use of
a high single dose. Three-dimensional treatment planning
is not (yet) available, treatment documentation can be
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difficult and finally doing IORT is a major interdisciplinary
effort and therefore only available at large centers [23].
Typically single doses of 10–20 Gy are used. However,
the conversion of high single doses into biologic equiva-
lent doses in fractionated therapy is difficult. For ex-
ample, a single dose of 15 Gy would be equivalent to
31–54 Gy in conventionally fractionated RT regarding
tumor and late reacting tissue response using the linear-
quadratic model and assuming alpha/beta values of 3–10
[18, 19]. However the linear quadratic model is not vali-
dated for high single doses and probably overestimates the
equivalent fractionated dose [25, 26]. Further on there is
growing evidence for a different tissue reaction to high
single doses per se if a threshold of 8–10 Gy is exceeded
[27]. Taken alternative models [26] and the clinical experi-
ence into account, it seems more reliable to assume an
equivalent fractionated dose which is 2–3 fold the IORT
dose, while the tumor effect seems rather 2 fold and the
late reacting tissue effect rather 3-fold. This underlines the
need for optimal sparing of organs at risk and the combin-
ation of IORT with EBRT whenever feasible.
IORT in pancreatic cancer: The Beginning
Initial studies were conducted at the University of Kyoto.
In these early studies resection was followed by IORT
doses of 25–30 Gy [28]. Nishimura et al. reported an im-
provement in survival and pain relief in a series of pa-
tients with advanced pancreatic cancers treated with
IORT doses of 20–40 Gy compared with the control
arm [29]. These studies prompted further investigations.
Shipley et al. evaluated 20 Gy IORT in patients with
unresectable disease in combination with EBRT. Median
survival was 16.5 month with approximately 50% of pa-
tients achieving pain relief [30]. Roldan et al. retrospect-
ively evaluated 159 patients treated between 1974 and
1985 with IORT in addition to postoperative EBRT.
Local control was improved at both 1- and 2-year time
points, though not overall survival [31].
Safety of IORT in pancreatic cancer
Importantly, the addition of IORT after surgery did not
increase perioperative complication rates significantly.
Although late complications have been reported after
IORT for pancreatic cancer, all reports suggest that
IORT may be delivered safely even in combination with
surgical resection (Tables 1 and 2) [20]. Selection of ra-
diation doses for IORT was influenced by seminal, pre-
clinical canine experiments performed at the National
Cancer Institute that provided an understanding of nor-
mal tissue tolerances, including surgically manipulated
Fig. 1 Intraoperative radiation Therapy with electrons (IOERT). Placement of an intraoperative electron beam applicator in a patient with pancreatic
cancer. An applicator of appropriate size is chosen, manually positioned and attached to the table. Applicators are made of steel or plastic to restrict
the radiation field laterally and are usually available in different sizes, shapes and bevel angles. Prior to irradiation, the axis of the applicator has to be
aligned properly with axis of the LINAC in a defined distance. The dose is usually prescribed to the 90% isodose
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tissues, for IORT [21, 32]. These studies created a foun-
dation for the rational delivery of IORT in humans, so it
should not be surprising that clinical studies have shown
these RT doses to be safe and feasible.
IORT in resectable disease
In a prospective, randomized trial conducted at the Na-
tional Cancer Institute (NCI) (Sindelar et al.) 24 patients
were randomized to receive IORT (20Gy) with EBRT
(satges II-IV). Excluding 7 perioperative deaths, an im-
provement in local control and median survival was seen
in the patients who received IORT (OS 18 vs 12 month;
p = 0.01) [33].
All other data regarding IORT in resectable disease
are limited to retrospective single- or multi-institutional
series (Table 1). Of those several have evaluated out-
comes in patients who have undergone resection for
pancreatic cancer, comparing cohorts who received
IORT versus no IORT. Nearly all of them show a benefit
due to reduced locoregional recurrence by the addition
of IORT around 40–80% (Table 1).
Zerbi et all reported 90 patients who underwent resec-
tion between 1985 and 1993. 43 patients received IORT
in addition to surgical resection. IORT doses were
between 12.5 and 20 Gy. Results revealed similar tumor-
size and overall stage between both groups and no dif-
ference in operative mortality and early postoperative
complications. Local recurrence in the IORT group was
27% compared to 56% in the surgery only group whereas
there was no statistically significant difference in overall or
disease free survival [34]. Alfieri et al. evaluated 46 pa-
tients, of which the last 26 received IORT and adjuvant
EBRT. Medium survival was 10.8 month in the surgery
group and 14.4 month in the surgery and IORT group
(p = 0.06). The 5-year local control was significantly better
in the IORT group with 30% vs. 58% (p < 0.01). Multivari-
ate analysis demonstrated that IORT was an independent
prognostic factor for local control [35]. Reni et al. evalu-
ated a larger series with 127 patients receiving IORT after
surgery and compared these with a cohort of 76 patients
with surgery alone. As in the other studies no additional
operative morbidity and mortality was observed due to
the addition of IORT. In Stage I and II disease IORT sig-
nificantly prolonged time to local failure, time to failure
and overall survival [36]. Additional data from 2 larger
multi-institutional series confirmed the favourable effect
of IORT on local control [37, 38].
These studies are summarized in Table 1 and suggest
an improvement in local control due to IORT without
additional operative morbidity or mortality.
IORT in locally advanced or unresectable disease
In locally advanced pancreatic cancer (LAPC) the role of
IORT is more clearly defined. Many studies have
Fig. 2 Beams eye view though a intraoperative electron beam applicator to the tumor bed after resection of a locally advanced pancreatic cancer
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Table 1 Selected studies of Intraoperative Radiotherapy in resected pancreatic cancer
Studies Number IORT Dose (Gy) EBRT Operative
mortality
Peri-/ postoperative
complications
Local recurrence Overall survival
(Median)
Sindelar et al. [33] 24 20 100%
12 Surgery and EBRT 100% 12 month
12 Surgery and IORT
or EBRT
33% 18 month
Zerbi et al. [34] 90 12.5–20 36%
47 Surgery 2.1% 23.4% 56,4% 12 month
43 Surgery and IORT 2.3% 23.2% 26% 19 month
Alfieri et al. [35] 46 10 67%
20 Surgery 8% 43% 71.2 10.8 month
26 Surgery and IORT 9% 57% 41.6% 14.3 month
Reni et al. [36] 203 10–25 28% Median time to
76 Surgery 4% 45% local failure 12 month
127 Surgery and IORT 5% 39% 11 month
14 month
15.5 month
Ogawa et al. [37] 210 30% 63% 16.3% 19.1 month
All patients Surgery and
IORT
Valentini et al. [38] 270
All patients surgery and
IORT
7.5–25 63% Median time to local
failure 15 month
19 month
Showalter et al. [47] 99 10–20
46 Surgery + − EBRT 66% 40% 39% 19.2 month
37 surgery IORT + −
EBRT
74% 46% 21% 21 month
Table 2 Selected studies of Intraoperative Radiotherapy in locally advanced/unresectable pancreatic cancer
Studies Number IORT Dose (Gy) Local Recurrence Overall Survival (Median)
Roldan et al. [31] 159 20
122 EBRT 52% 12.6 month
37 EBRT and IORT 18% 13.4 month
Tepper et al. [39] 51
EBRT and IORT
20 Not assessable 9 month
Willet et al. [40]
Cai et al. [41]
194
EBRT and IORT
15–25 2 y
59%
12 month
Mohiddin et al. [48] 49
EBRT and IORT
10–20 29% 16 month
Schuricht et al. [49] 105
76 EBRT and IORT
29 EBRT
15–20 30% 15–20 month
Keane et al. [45] 85 (locally advanced/Borderline resectable) 10–20
26 IORT 20.5 month
49 resected
24 surgery and IORT 35.1 month
25 surgery 301.1 month
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documented both safety and pain control with IORT,
resulting in complete pain resolution in 75–90% of cases
(Table 2) [20]. Nishimura et al. were among the first to
show that the addition of IORT in advanced pancreatic
cancer lead to a significant improvement in pain relief
compared to a control group [29]. A study from Mayo
Clinic evaluated 159 patients with unresectable pancre-
atic cancer who underwent exploratory laparotomy. Of
these 37 received EBRT in combination with IORT
boost. The addition of IORT to EBRT resulted in a 1-
year local control of 82% compared to 48% with EBRT
alone. Despite this benefit there was no difference in
median or long-term survival [31].
Radiation Therapy Oncology Group (RTOG) tried to
evaluate IORT in LAPC in a multi-institutional study.
RTOG 8505 evaluated the role of IORT in addition to
EBRT for patients with LAPC. The rate of major postop-
erative complications was 12% and median survival was
9 month. Local control could not adequately be evalu-
ated in this study. This Study demonstrated the feasibil-
ity of IORT, but did not clearly show an advantage of
IORT over conventional therapy [39].
Larger single institutional series have published long-
term results with the use of IORT. Since 1978, patients
with LAPC with good performance status have been con-
sidered for consolidative intraoperative radiotherapy
(IORT) at the Massachusetts General Hospital (MGH) [4].
In 2005, Willett et al. reported that among the first 150
patients with LAPC to receive IORT at MGH as part of
their treatment, the 1-year, 2-year, and 3-year overall sur-
vival (OS) rates were 54, 15%, and 7%, respectively. It is
worth noting that 5 patients survived past 5 years [40]. In
an updated publications of 194 consecutive patients with
unresectable LAPC comparable to previously published
values were reported with 1-year, 2-year, 3-year, and 5-
year OS rates of 49, 16, 6, and 3%, respectively [8, 9].
Multivariate analysis showed that low comorbidity index
and chemotherapy predicted improved overall survival,
with a median OS of 21.2 months and a 3-year OS rate of
20% in this subgroup [41].
Novel systemic treatment regimens like FOLFIRINOX
and nab-paclitaxel have demonstrated improvements in
prolonging survival also in advanced cases [17, 18]. The
strength of chemotherapy as a positive prognostic factor
for survival in current studies supports the emphasis on
upfront systemic treatment of patients with pancreatic
cancer, but long-term survival is still scarce, whereas the
role of radiation therapy remains controversial [7, 8].
The 2009 an autopsy analysis by Iacobuzio-Donahue
et al. demonstrated that local tumor progression causes
significant morbidity and mortality in patients with
unresectable and even metastatic pancreatic cancer [42]
leading again to increased attention on the role of local-
ized treatment, i.e. localized radiotherapy.
Improved outcomes with novel chemotherapy regimes
in the treatment of metastatic pancreatic cancer have
prompted incorporation of these regimens into neoadju-
vant treatment [43, 44]. While some patients are still
found to be unresectable after neoadjuvant treatment,
others are able to undergo resection [44]. In 2016
Massachusetts General Hospital (MGH) reported retro-
spectively analyzed records of 85 patients with locally
advanced/ borderline resectable PDAC who received
neoadjuvant treatment with chemotherapy and/or che-
moradiotherapy followed by surgical exploration in an
IORT-equipped operating suite between 2010 and 2015.
Of 85 patients, 49 (57.6%) underwent resection after
neoadjuvant treatment, 27 (31.8%) were unresectable,
and 9 (10.6%) were found to have distant metastases. 24
of 49 patients who underwent resection received IORT
for close/positive margins on intraoperative frozen sec-
tion. There was no significant difference in operative
times, postoperative complications, or operative morbid-
ity in patients who underwent resection and IORT vs
those who underwent resection alone. Median OS was
31.1 months in patients who underwent resection alone
and 35.1 months in patients who underwent resection
and IORT. Despite the increased incidence of close/
positive margins in patients who underwent resection
and IORT, the rates of local recurrence were similar to
those who underwent resection alone. 26 of 27 patients
with unresectable disease upon exploration received
IORT. Median OS was 20.5 months [45].
These studies are summarized in Table 2. IORT in pa-
tients with unresectable pancreatic cancer show that most
patients experience pain relief and improved local control.
IORT in locally recurrent disease
A retrospective study from the University of Heidelberg
reported 36 patients with isolated local recurrences of
pancreatic cancer who have been treated with a combin-
ation of surgery, IORT and EBRT. Median time from ini-
tial treatment to recurrence was 20 months. All patients
were surgically explored. In 18 patients a gross total re-
section was achieved, whereas the other half received
only debulking or no resection at all. All patients re-
ceived IORT with a median dose of 15 Gy. Additional
EBRT was applied to 31 patients with a median dose of
45 Gy, combined with concurrent, mainly gemcitabine-
based chemotherapy. Local progression was found in 6
patients after a median time of 17 months, resulting in
estimated 1- and 2-year local control rates of 91 and
67%, respectively. Distant failure was observed in 23 pa-
tients, mainly in liver or peritoneal space. The median
estimated progression-free survival was 9 months with
1- and 2-year rates of 40 and 26%, respectively. They
found an encouraging estimated median overall survival
of 19 months, transferring into 1- and 2-year rates of 66
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and 45%. Notably 6 of 36 patients (17%) lived for more
than 3 years. Severe postoperative complications were
found in 3 and chemoradiation-related grade III toxicity
in 6 patients. No severe IORT related toxicity was ob-
served. Combination of surgery, IORT and EBRT in pa-
tients with isolated local recurrences of pancreatic
cancer resulted in encouraging local control and overall
survival with acceptable toxicity [46]. This approach
seems to be superior to palliative chemotherapy or che-
moradiation alone and should be considered in an other-
wise difficult to treat group of patients.
Conclusion
In summary, the available data demonstrates that IORT
is a safe addition to the treatment of pancreatic cancer
and standard neoadjuvant or adjuvant therapies, with
the intention of improving local control for patients with
resectable pancreatic cancer. Series of patients with
unresectable pancreatic cancer show that most patients
experience pain relief and improved local control. In se-
lect studies inclusion of IORT led to improved survival.
Improved outcomes with novel chemotherapy regimens
led again to increased attention on the role of localized
radiotherapy, since local tumor progression causes signifi-
cant morbidity and mortality in patients. Intraoperative
radiation therapy (IORT) techniques allow increasing the
effective radiation dose and improving local tumor con-
trol. However, at present, no phase III data clearly defines
the role of IORT in the management of pancreatic cancer.
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